

1 **Regional Variation in the Interpretation of Contact Precautions for Multidrug-**  
2 **resistant Gram-negative bacteria: a cross-sectional survey**

3 **Anneloes van Veen<sup>1</sup>, Inge de Goeij<sup>1</sup>, Marjolein Damen<sup>2</sup>, Elisabeth G.W. Huijskens<sup>3</sup>, Sunita Paltansing<sup>4</sup>,**  
4 **Michiel van Rijn<sup>5</sup>, Robbert G. Bentvelsen<sup>6,7</sup>, Jacobien Veenemans<sup>3,8</sup>, Michael van der Linden<sup>9</sup>, Margreet**  
5 **C. Vos<sup>1</sup> and Juliëtte A. Severin<sup>1\*</sup> on behalf of the Infection Prevention and Antimicrobial Resistance**  
6 **Care Network South-western Netherlands.**

7 \* Corresponding author: [j.severin@erasmusmc.nl](mailto:j.severin@erasmusmc.nl)

8

9 <sup>1</sup> Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Centre,  
10 Rotterdam, The Netherlands.

11 <sup>2</sup> Department of Medical Microbiology, Maastad General Hospital, Rotterdam, The Netherlands.

12 <sup>3</sup> Department of Medical Microbiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

13 <sup>4</sup> Department of Medical Microbiology and Infection Prevention, Franciscus Gasthuis & Vlietland,  
14 Rotterdam, The Netherlands.

15 <sup>5</sup> Department of Medical Microbiology and Infectious Diseases, Ikazia Hospital, Rotterdam, The  
16 Netherlands.

17 <sup>6</sup> Department of Infection Prevention, Zorgsaam Hospital, Terneuzen, The Netherlands.

18 <sup>7</sup> Microvida Laboratory for Microbiology, Amphia Hospital, Breda, The Netherlands.

19 <sup>8</sup> Department of Infection Prevention, Admiraal de Ruyter Hospital, Goes, The Netherlands.

20 <sup>9</sup> Department of Infection Prevention, IJsselland Hospital, Capelle aan den IJssel, The Netherlands.

## 21 **Summary**

22 **Background:** Contact precautions (CP) are recommended when caring for patients with carbapenemase-  
23 producing Enterobacterales (CPE), carbapenemase-producing *Pseudomonas aeruginosa* (CPPA), and  
24 extended-spectrum  $\beta$ -lactamase-producing Enterobacterales (ESBL-E).

25 **Aim:** Our aim was to determine the interpretation of CP and associated infection prevention and control  
26 (IPC) measures in the non-ICU hospital setting for patients with CPE, CPPA or ESBL-E in 11 hospitals in the  
27 Southwest of the Netherlands.

28 **Methods:** A cross-sectional survey was developed to collect information on all implemented IPC  
29 measures, including use of personal protective equipment, IPC measures for visitors, cleaning and  
30 disinfection, precautions during outpatient care and follow-up strategies. All eleven hospitals were invited  
31 to participate between November 2020 and April 2021.

32 **Findings:** The survey was filled together with each hospital. All hospitals installed isolation precautions for  
33 patients with CPE and CPPA during inpatient care and day admissions, whereas ten hospitals (90.9%)  
34 applied isolation precautions for patients with ESBL-E. Gloves and gowns were always used during physical  
35 contact with the patient in isolation. Large variations were identified in IPC measures for visitors, cleaning  
36 and disinfection products used, and precautions during outpatient care. Four hospitals (36.4%) actively  
37 followed up on CPE or CPPA patients with the aim to declare them CPE- or CPPA-negative as timely as  
38 possible, and two hospitals (20.0%) actively followed up on ESBL-E patients.

39 **Conclusion:** CP are interpreted differently between hospitals, leading to regional differences in IPC  
40 measures applied in clinical settings. Harmonizing infection-control policies between the hospitals could  
41 facilitate patient transfers and benefit collective efforts of preventing transmission of MDR-GNB.

42

43 **Keywords:** Carrier state, Enterobacteriaceae, Hospitals, Infection control, Multidrug resistance, Patient  
44 isolation, *Pseudomonas aeruginosa*

## 45 Introduction

46 Multidrug-resistant Gram-negative bacteria (MDR-GNB), including carbapenemase-producing  
47 Enterobacterales (CPE), carbapenemase-producing *Pseudomonas aeruginosa* (CPPA), and extended-  
48 spectrum  $\beta$ -lactamase-producing Enterobacterales (ESBL-E), are well-known causes of healthcare-  
49 associated infections. Infections with MDR-GNB are more difficult to treat compared to infections with  
50 susceptible Gram-negative bacteria, and are, therefore, associated with high morbidity and mortality [1-  
51 3]. In the Netherlands, CPE and CPPA are rare, with only sporadic outbreaks in Dutch hospitals [4]. ESBL-  
52 E are more often found, but prevalences are still low in comparison to other European countries [4-6].

53 Infection prevention and control (IPC) measures are essential to prevent or control nosocomial spread of  
54 MDR-GNB. While there is in general international consensus on the application of contact precautions  
55 (CP), in addition to standard precautions, when caring for patients colonized or infected with MDR-GNB,  
56 international guidelines show some variation in their recommendations on related IPC measures, e.g.,  
57 which personal protective equipment (PPE) healthcare workers (HCW) should use and when [7-14]. Also,  
58 IPC measures needed in specific settings (e.g., during outpatient care or physiotherapy of a hospitalized  
59 patient) and for different patient populations, are often not described, possibly due to a lack of studies in  
60 these specific situations and, consequently, paucity of evidence [11, 15, 16].

61 Besides variation in or lack of recommendations on certain IPC measures in infection-control guidelines,  
62 substantial variation in implemented IPC measures by healthcare facilities has been reported as well, both  
63 at the national and international level [11, 16-18]. Major differences were found, for example, in IPC  
64 measures between hospitals in a small geographical area [19]. The Infection Prevention and Antimicrobial  
65 Resistance (IP & AMR) Care Network South-western Netherlands is likewise a small geographical area,  
66 with a relatively large number of hospitals [20]. Patients are frequently transferred between these  
67 hospitals, which is a known risk factor for transmission of multidrug-resistant bacteria, and therefore  
68 necessitates a collaborative approach with consensus on IPC measures to prevent or control spread [15,  
69 21-23]. The aim of this study was to determine the interpretation of CP and associated IPC measures in  
70 the non-ICU hospital setting for patients colonized or infected with CPE, CPPA or ESBL-E in the Southwest  
71 of the Netherlands.

## 72 **Methods**

### 73 *Setting*

74 This study was performed within the IP & AMR Care Network South-western Netherlands, which was  
75 established in 2015 as part of the Dutch AMR National Action Plan [24]. The eleven hospitals from the IP  
76 & AMR Care Network South-western Netherlands were invited to participate in this study, including one  
77 university hospital, six non-university teaching hospitals and four non-teaching hospitals (Supplementary  
78 Table A1).

### 79 *Survey*

80 We developed a cross-sectional survey to collect information on the IPC measures embedded in the  
81 hospitals' internal IPC policies for nine multidrug-resistant microorganisms (MRDO) [9]. Here, we only  
82 report on the IPC measures for CPE, CPPA, and ESBL-E. The survey focused on a variety of topics, including  
83 flagging of carriers in the electronic health record (EHR); isolation precautions during inpatient care, day  
84 admissions, and outpatient care; IPC measures for visitors of inpatients; terminal cleaning and  
85 disinfection; and follow-up of carriers and conditions for cessation of isolation measures. The majority of  
86 questions were multiple-choice, yet more detailed explanations could be given if necessary.

87 The survey was filled out together with one or multiple infection prevention practitioner(s) from each  
88 hospital during an online meeting between November 2020 and April 2021. In preparation of the meeting,  
89 the participants received the survey. After the meeting, the filled survey was sent to them by email to  
90 check whether the survey was filled out correctly. If necessary, answers could be added and modified  
91 after which the survey was sent back to the research team for analysis.

### 92 *Definitions*

93 Supplementary Table A2 provides an overview of the IPC measures recommended by national and  
94 international IPC guidelines for CPE, CPPA, and ESBL-E. The Dutch guidelines describe different types of  
95 isolation, including strict isolation and contact isolation [25-27]. Currently, the Dutch MDRO guideline for  
96 hospitals indicates that inpatients with CPE, CPPA, and ESBL-E should be cared for in contact isolation, and  
97 specifically recommends using single-occupancy rooms when caring for patients with CPE [27]. Strict  
98 isolation is only recommended for multidrug-resistant *Acinetobacter* species. Furthermore, the Dutch  
99 MDRO guideline prescribes standard precautions, not targeted contact precautions, for patients visiting  
100 the outpatient clinic. Cessation of isolation measures is not recommended during hospitalization,

101 although it could be considered if isolation is a major burden for the patient’s wellbeing and/or treatment.  
102 In this case, two negative culture sets, with at least 24 hours in between, are required [27].

103 For the follow-up of MDR-GNB carriers, active, passive and no follow-up are distinguished. Active follow-  
104 up is defined as requesting all MDR-GNB carriers to participate in taking screening cultures and actively  
105 following them with the aim to declare patients MDR-GNB-negative as timely as possible. During passive  
106 follow-up, however, patients only receive screening cultures on indication by the treating physician (e.g.,  
107 when long-term isolation is detrimental to the patient’s health and/or treatment) in order to safely  
108 discontinue isolation measures following consecutive negative culture sets or are screened upon hospital  
109 admission. Hospitals not pursuing active or passive follow-up are categorized as no follow-up.

#### 110 *Statistical analysis*

111 IBM Statistical Package for the Social Sciences Solutions (SPSS) version 28 (IBM Corp., Armonk, New York,  
112 USA) was used for the analyses. Missing data are reported as such. For descriptive purposes, frequencies  
113 and percentages were calculated, where appropriate.

## 114 **Results**

### 115 **Carbapenemase-producing Enterobacterales & carbapenemase-producing *Pseudomonas*** 116 ***aeruginosa***

#### 117 *Inpatient care and day admissions*

118 The survey was filled together with each of the 11 hospitals. All hospitals flagged patients colonized or  
119 infected with CPE and CPPA in their EHR. Infection-control policies for CPE and CPPA were in place in each  
120 hospital, however, the number and strength of IPC measures applied varied (Table I). During inpatient  
121 care and at day admissions, different types of isolation were applied: eight hospitals (72.7%) applied  
122 contact isolation, one hospital (9.1%) applied strict isolation, and two hospitals (18.2%) applied so-called  
123 “contact-plus” isolation (Table I). “Contact-plus” isolation is not defined in any national or international  
124 guideline. It is defined as isolation with measures that are in-between contact and strict isolation, as  
125 defined in the Dutch guidelines, but it is applied differently in two hospitals [25-27]. At hospital 8, the  
126 patient room’s door had to remain closed during “contact-plus” isolation, but could be open during  
127 contact isolation. “Contact-plus” isolation in hospital 1 differed from contact isolation in terms of the  
128 isolation measures required during outpatient care and the IPC measures for visitors. However, all  
129 hospitals that installed contact isolation for CPE and CPPA carriers also applied stricter measures than the

130 Dutch contact isolation guideline prescribes (e.g., requiring HCWs to also wear a gown besides only gloves  
131 or requiring the patient room's door to be closed), without defining it "contact-plus" isolation [26].

132 Most hospitals isolated CPE and CPPA patients during inpatient care in single-occupancy rooms with  
133 private bathrooms (n=10, 90.9%). While according to the Dutch guidelines an isolation room is only  
134 necessary for strict isolation, one hospital (9.1%) reported isolating CPE and CPPA carriers in isolation  
135 rooms, but still used the term contact isolation (Table I) [25]. Patients were preferably isolated in single-  
136 occupancy rooms during day admissions (n=9, 81.8%), although shortage of such rooms could necessitate  
137 isolation in multiple-occupancy rooms (n=1, 9.1%).

138 Although in five hospitals (45.5%) the decision for HCW to put on PPE before entering a patient's room  
139 depended on whether contact with the patient was anticipated or not, in other hospitals HCW were  
140 required to wear PPE at all times when entering the patient's room (n=6, 54.5%). Overall, ten hospitals  
141 (90.9%) were more stringent compared to the Dutch contact isolation guideline, which requires HCW to  
142 wear only gloves before having contact with the patient and/or the patient's environment [26].

#### 143 *Outpatient care*

144 Four hospitals (36.4%) only used standard precautions when patients with CPE or CPPA visited the  
145 outpatient clinic. Hospital 1 (9.1%) consistently applied "contact-plus" isolation during outpatient care  
146 (policy 1), while the other six hospitals (54.5%) followed different approaches to determine the type of  
147 isolation (policy 2-5; Figure 1). These decisions depended on the type of patient visiting the outpatient  
148 clinic, the type of procedure being performed, and/or on whether there would be physical contact with  
149 the patient. In general, contact isolation was applied during invasive procedures and inpatients were  
150 continued to be cared for in contact isolation when visiting the outpatient clinic. During contact isolation,  
151 HCW were wearing a disposable gown and non-sterile gloves (Figure 1).

#### 152 *IPC measures for visitors*

153 Visitors were requested to take precautions when visiting an inpatient with CPE or CPPA in all hospitals,  
154 ranging from hand disinfection (n=11, 100%) to, additionally, wearing a surgical mask, disposable gown,  
155 non-sterile gloves and hair cap as the most extensive IPC measures (n=1, 9.1%). In four hospitals (36.4%),  
156 visitors could temporarily leave a patient's room during their visit. Rooming-in was permitted in most  
157 hospitals (n=10, 90.9%), of which five hospitals (50.0%) allowed rooming-in visitors to temporarily leave  
158 the patient's room (Supplementary Table A3).

159 *Cleaning & disinfection*

160 Different cleaning and disinfection products were used (Supplementary Table A4). Most hospitals (n=9,  
161 81.8%) replaced the separation curtains after cessation of isolation measures. One hospital (9.1%) also  
162 changed the window curtains (Supplementary Table A4).

163 *Follow-up of carriage and conditions for cessation of isolation measures*

164 Various follow-up strategies were used (Table II). Active follow-up was done by four hospitals (36.4%),  
165 wherein patients received a self-sampling set at home at different time intervals. Three hospitals (75.0%)  
166 initiated active follow-up two months after a positive culture, yet one hospital (25.0%) started at least one  
167 year after the last positive culture. The number of swabs needed to declare a patient CPE- or CPPA-  
168 negative varied between these four hospitals, from one negative culture to six consecutive negative  
169 culture sets. Passive follow-up was performed in another four hospitals (36.4%). These hospitals all used  
170 two consecutive negative cultures or culture sets for lifting isolation measures, but the initiation of follow-  
171 up varied from at least 48 hours after stopping relevant antibiotics to at least one year after the last  
172 positive culture. Although negative cultures could lead to declaring a patient CPE- or CPPA-negative  
173 followed by cessation of isolation measures, two hospitals (50.0%) continued to flag patient's EHR  
174 indicating former CPE- or CPPA-carriage. Three hospitals (27.3%) did not follow up on CPE or CPPA carriers  
175 and flagged patient's EHR indefinitely (Table II).

176 **Extended-spectrum  $\beta$ -lactamase-producing Enterobacterales**

177 *Inpatient care and day admissions*

178 Patients with ESBL-E were also flagged in each hospital's EHR. Hospital 2 (9.1%) did not apply isolation  
179 precautions for ESBL-E carriers (Table I). Hospital 1 (9.1%) placed all patient groups with ESBL-E during  
180 inpatient care in contact isolation, whereas isolation precautions varied for different patient groups during  
181 day admissions. Inpatients undergoing a procedure at the day admissions centre remained in contact  
182 isolation, whereas patients coming from home were cared for taking only standard precautions. Hospital  
183 10 (9.1%) installed contact isolation for ESBL-E patients during inpatient care, yet "contact-plus" isolation  
184 during day admissions. Lastly, eight hospitals (72.7%) applied contact isolation for all patients with ESBL-  
185 E during both inpatient care and day admissions. Although a single-occupancy room with private  
186 bathroom remained preferable for inpatients with ESBL-E (n=8, 72.7%), several hospitals (n=6, 54.5%) also  
187 allowed these patients to stay in a multiple-occupancy room with or without dedicated bathroom due to  
188 shortage of single-occupancy rooms (Table I).

189 The policy of PPE use by HCW was more constant over the hospitals. Approximately 70% of hospitals (n=8)  
190 did not require HCW to wear any PPE upon room entrance when no patient contact was anticipated, while  
191 ten hospitals (90.9%) required HCW to wear a gown and gloves when contact was anticipated (Table I).

#### 192 *Outpatient care*

193 Six hospitals (54.5%) did not take isolation precautions for ESBL-E carriers during outpatient care (Figure  
194 1). Hospital 1 and 11 (18.2%) only placed inpatients with an appointment at the outpatient department in  
195 contact isolation, whereas outpatients were cared for using only standard precautions (policy 4). The  
196 other three hospitals (27.3%) followed a similar two- or three category approach as used for patients with  
197 CPE and CPPA (policy 2, 3, and 5; Figure 1).

#### 198 *IPC measures for visitors*

199 Ten hospitals (90.9%) requested visitors to apply IPC measures, of which all hospitals imposed hand  
200 disinfection. Hospital 10 (10.0%) asked visitors to additionally wear a gown and gloves. Rooming-in was  
201 allowed in most hospitals (n=9, 81.8%). Whether temporary room leave by visitors was allowed, varied  
202 depending on the underlying reason and whether it was a regular or rooming-in visitor (Supplementary  
203 Table A3).

#### 204 *Cleaning & disinfection*

205 A variety of cleaning and disinfection products was used after cessation of isolation measures  
206 (Supplementary Table A4). The separation curtains were replaced in seven hospitals (63.6%), while none  
207 of the hospitals changed the window curtains after cessation of isolation measures (Supplementary Table  
208 A4).

#### 209 *Follow-up of carriage and conditions for cessation of isolation measures*

210 Four different strategies were used for follow-up of ESBL-E carriers (Table III). Two hospitals (18.2%)  
211 performed an active follow-up with varying duration and number of culture sets required. Whereas  
212 hospital 1 required two negative culture sets starting two months after the first positive culture with three  
213 days between culture sets, hospital 5 required one negative culture set at least one year after the last  
214 positive culture. Passive follow-up of ESBL-E carriers was performed by six hospitals (54.5%), with three  
215 hospitals (50.0%) screening on indication by the treating physician and three hospitals (50.0%) upon  
216 hospital admission. The former three hospitals all required two negative culture sets for the safe cessation



217 of isolation measures, although the timing of when to start culturing varied. Two hospitals (18.2%) did not  
218 pursue any follow-up and unflagged the EHR automatically after one year.

## 219 **Discussion**

220 This study showed substantial variation in the interpretation of CP and associated IPC measures for  
221 patients with CPE, CPPA and ESBL-E in the non-ICU setting in hospitals in the Southwest of the  
222 Netherlands. Unsurprisingly, most variation was observed in the IPC measures applied in clinical settings,  
223 which are not well-defined in national and/or international guidelines.

224 The hospitals had different interpretations of CP, which is particularly highlighted by the introduction of  
225 a new type of isolation, “contact-plus” isolation, and the variation observed in associated IPC measures  
226 outlined in each hospital’s internal IPC policies. Similar to previous findings, most and most stringent IPC  
227 measures are applied for patients with CPE and CPPA compared to ESBL-E [11, 18, 19]. Variability in the  
228 type of room used, types of PPE used by HCW, and environmental cleaning regimens were demonstrated  
229 between hospitals for each MDR-GNB, which also confirms findings from previous studies [11, 16-19].  
230 Moreover, considerable variation was observed in the IPC measures taken during outpatient care, with  
231 some hospitals installing no isolation precautions and other hospitals following a stepwise approach to  
232 determine which type of isolation, if any, was required for each patient.

233 Evidence-based recommendations on follow-up of MDR-GNB carriers and conditions for safe cessation of  
234 isolation measures are unavailable in international infection-control guidelines, possibly due to scarcity of  
235 data on the duration of colonization and the occurrence of relapse of recolonization. The Dutch MDRO  
236 guideline also offers limited guidance [27]. This is reflected in the large variety of follow-up strategies  
237 within our region, which varied from actively reaching out to patients with the aim to declare patients  
238 MDR-GNB-negative as timely as possible to no follow-up and flagging the EHR indefinitely. [28-31]. A  
239 direct comparison between different follow-up strategies in terms of duration and number of culture sets  
240 could be of added value in efforts to harmonize follow-up strategies.

241 In general, variation in implemented IPC measures on international, national, and regional levels, seems  
242 to depend on the availability of IPC guidelines for MDR-GNB, the evidence-base and level of detail of the  
243 IPC measures recommended in these guidelines, local context and epidemiology, and organizational  
244 resources (e.g., number and availability of single-occupancy rooms and personnel) [16-19]. National and  
245 international guidelines are available, yet, in practice, individual hospitals seem to apply the  
246 recommended measures quite differently. For example, hospital 2 does not apply CP for ESBL-E carriers,

247 which is not in line with both the Dutch and European Society of Clinical Microbiology and Infectious  
248 Diseases (ESCMID) guidelines (with the exception of *Escherichia coli*), and the active follow-up performed  
249 by several hospitals is not described in any national or international guideline whatsoever. Some regional  
250 differences can be explained by the patient populations served by the hospitals. Hospital 1 and 4, for  
251 example, provide tertiary care for critically-ill patients, resulting in a more intensive follow-up to prevent  
252 nosocomial transmissions among their vulnerable patients. The smaller hospitals may have less resources  
253 available and are, therefore, restricted in pursuing such intensive efforts. Also, hospital 1 and 4 have 100%  
254 adult single-occupancy rooms available, whereas the other, especially smaller, hospitals may need to  
255 deviate from their own and other hospitals' policies, by occasionally placing MDR-GNB-positive patients  
256 in multiple-occupancy rooms due to shortage of single-occupancy rooms.

257 The observed regional variety shows the need to harmonize IPC measures, since one hospital's actions (or  
258 non-actions) may impact other hospitals in the region that share patients [32]. Harmonizing measures,  
259 including conditions for cessation of isolation measures, may have a positive effect on MDR-GNB  
260 prevalence, may facilitate inter-hospital communication, provides HCWs clarity during patient transfers,  
261 and can lead to quicker and more effective actions to prevent or stop MDR-GNB spread between hospitals  
262 [19, 33, 34]. Also, it may cause more understanding and acceptance of IPC measures by patients (and their  
263 visitors) when they receive care in different hospitals, which may cause higher compliance with the  
264 installed measures. Research has shown that enhanced coordination in infection prevention within a  
265 region leads to greater synergistic effects, benefiting both individual hospitals and the entire region [32,  
266 35-37].

267 However, which particular IPC measures are most effective and should thus be prioritised in specific  
268 settings remains somewhat unclear. Studies on the effectiveness of CP often lack information on the  
269 details of CP applied in specific settings, complicating the interpretation of their results [38, 39]. For  
270 example, whether a dedicated bathroom was used and whether terminal cleaning and disinfection of that  
271 bathroom was performed after cessation of isolation measures is frequently not described, while its  
272 importance is increasingly recognized. Therefore, authors should provide more details about which  
273 specific IPC measures are considered part of CP in their studies.

#### 274 *Strengths and limitations*

275 A strength of this study is its multicentre design, with all hospitals in our region participating. This allowed  
276 for a comprehensive overview of the IPC measures applied in the hospitals. Additionally, the

277 extensiveness of the survey enabled us to uncover and compare details of IPC components associated  
278 with CP and isolation. A limitation of this study is that we did not ask the hospitals about the underlying  
279 reasons for choices made regarding their IPC policies. Future efforts should be aimed at harmonizing  
280 regional IPC policies, followed by measurement of each hospital's compliance with these policies.

## 281 **Conclusions**

282 Hospitals in the Southwest of the Netherlands reported considerable variation in the interpretation of CP  
283 and associated IPC measures when caring for patients with CPE, CPPA and ESBL-E. Heterogeneity in  
284 policies appeared most prevalent for isolation precautions during outpatient care and follow-up of  
285 carriers, which are not (well-)defined in national and/or international guidelines. Future research should  
286 explore the setting-specific reasons and risks related to these differences in IPC measures. Harmonizing  
287 infection-control policies between hospitals could facilitate patient transfers and benefit collective efforts  
288 of preventing MDR-GNB transmission.

289

## 290 **Acknowledgements**

291 The authors would like to acknowledge the contributions of Janet Vos, former network manager of the IP  
292 & AMR Care Network South-western Netherlands, and all infection prevention practitioners from  
293 participating hospitals.

## 294 **Conflict of interest**

295 The authors declare no conflict of interest.

## 296 **Source of funding**

297 The project was carried out within the Infection Prevention and Antimicrobial Resistance Care Network  
298 South-western Netherlands that receives funding from the Ministry of Health, Welfare and Sports.

## 299 References

- 300 [1] Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a  
301 systematic analysis. *Lancet* 2022;399(10325):629-55.
- 302 [2] Borer A, Saidel-Odes L, Riesenbergr K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate  
303 for carbapenem-resistant *Klebsiella pneumoniae* bacteremia. *Infect Control Hosp Epidemiol*  
304 2009;30(10):972-6.
- 305 [3] Saharman YR, Pelegrin AC, Karuniawati A, Sedono R, Aditjaningsih D, Goessens WHF, et al.  
306 Epidemiology and characterisation of carbapenem-non-susceptible *Pseudomonas aeruginosa* in a large  
307 intensive care unit in Jakarta, Indonesia. *Int J Antimicrob Agents* 2019;54(5):655-60.
- 308 [4] Nethmap/MARAN. NethMap 2021: Consumption of antimicrobial agents and antimicrobial  
309 resistance among medically important bacteria in the Netherlands. 2021.
- 310 [5] European Centre for Disease Prevention and Control. European Antimicrobial Resistance  
311 Surveillance Network (EARS-Net), [https://www.ecdc.europa.eu/en/about-us/networks/disease-](https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data)  
312 [networks-and-laboratory-networks/ears-net-data](https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data); 2021 [accessed April 4 2023].
- 313 [6] van der Schoor AS, Severin JA, Klaassen CHW, van den Akker JPC, Bruno MJ, Hendriks JM, et al.  
314 Universal screening or a universal risk assessment combined with risk-based screening for multidrug-  
315 resistant microorganisms upon admission: Comparing strategies. *PLoS One* 2023;18(7):e0289163.
- 316 [7] Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines  
317 for the management of the infection control measures to reduce transmission of multidrug-resistant  
318 Gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect* 2014;20 Suppl 1:1-55.
- 319 [8] Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory C.  
320 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care  
321 Settings. *Am J Infect Control* 2007;35(10 Suppl 2):S65-164.
- 322 [9] Kluytmans-Vandenbergh MF, Kluytmans JA, Voss A. Dutch guideline for preventing nosocomial  
323 transmission of highly resistant microorganisms (HRMO). *Infection* 2005;33(5-6):309-13.
- 324 [10] Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, et al. Infection  
325 prevention and control measures and tools for the prevention of entry of carbapenem-resistant  
326 Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention  
327 and Control. *Antimicrob Resist Infect Control* 2017;6:113.

- 328 [11] Lynch BL, Schaffer K. Can guidelines for the control of multi-drug-resistant Gram-negative  
329 organisms be put into practice? A national survey of guideline compliance and comparison of available  
330 guidelines. *J Hosp Infect* 2019;102(1):1-7.
- 331 [12] HSE Antimicrobial Resistance and Infection Control. Management and Control of  
332 Carbapenemase Producing Enterobacterales (CPE) in all Healthcare Settings. Dublin: HSE-AMRIC; ;  
333 December 2022.
- 334 [13] Otter JA, Mutters NT, Tacconelli E, Gikas A, Holmes AH. Controversies in guidelines for the  
335 control of multidrug-resistant Gram-negative bacteria in EU countries. *Clin Microbiol Infect*  
336 2015;21(12):1057-66.
- 337 [14] Centers for Disease Control. Facility guidance for control of carbapenem-resistant  
338 Enterobacteriaceae (CRE): November 2015 update - CRE Toolkit. 2015.
- 339 [15] European Centre for Disease Prevention and Control. Risk assessment on the spread of  
340 carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare  
341 facilities, with special emphasis on cross-border transfer. 2011.
- 342 [16] Tacconelli E, Buhl M, Humphreys H, Malek V, Presterl E, Rodriguez-Baño J, et al. Analysis of the  
343 challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in  
344 Europe. *BMJ Open* 2019;9(5):e027683.
- 345 [17] van Dijk MD, Voor In 't Holt AF, Alp E, Hell M, Petrosillo N, Presterl E, et al. Infection prevention  
346 and control policies in hospitals and prevalence of highly resistant microorganisms: an international  
347 comparative study. *Antimicrob Resist Infect Control* 2022;11(1):152.
- 348 [18] Gysin DV, Cookson B, Saenz H, Dettenkofer M, Widmer AF, Infections ESGfN. Variability in  
349 contact precautions to control the nosocomial spread of multi-drug resistant organisms in the endemic  
350 setting: a multinational cross-sectional survey. *Antimicrob Resist Infect Control* 2018;7:81.
- 351 [19] Tschudin-Sutter S, Lavigne T, Grundmann H, Rauch J, Eichel VM, Debocker S, et al. Differences  
352 in infection control and diagnostic measures for multidrug-resistant organisms in the tristate area of  
353 France, Germany and Switzerland in 2019 - survey results from the RH(E)IN-CARE network. *Swiss Med*  
354 *Wkly* 2021;151:w20454.
- 355 [20] Infectiepreventie & Antibioticaresistentie Zorgnetwerk Zuidwest-Nederland. Aanpak  
356 antibioticaresistentie en infectiepreventie Zuidwest-Nederland, <https://abrzorgnetwerkzwn.nl/>;  
357 [accessed Feb 13 2024].
- 358 [21] Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and  
359 the risk of multi-resistant bacterial infection. *Clin Infect Dis* 2011;53(1):49-56.

- 360 [22] Donker T, Wallinga J, Grundmann H. Patient referral patterns and the spread of hospital-  
361 acquired infections through national health care networks. *PLoS Comput Biol* 2010;6(3):e1000715.
- 362 [23] Ciccolini M, Donker T, Köck R, Mielke M, Hendrix R, Jurke A, et al. Infection prevention in a  
363 connected world: the case for a regional approach. *Int J Med Microbiol* 2013;303(6-7):380-7.
- 364 [24] Tweede Kamer der Staten-Generaal. Kamerbrief 32620, nr. 159. 2015.
- 365 [25] Dutch Working Party on Infection Prevention (WIP). Strikte isolatie. 2006.
- 366 [26] Dutch Working Party on Infection Prevention (WIP). Contactisolatie. 2006.
- 367 [27] Dutch Working Party on Infection Prevention (WIP). Bijzonder resistente micro-organismen  
368 (BRMO). 2012.
- 369 [28] van Dijk MD, Voor In 't Holt AF, Polinder S, Severin JA, Vos MC. The daily direct costs of isolating  
370 patients identified with highly resistant micro-organisms in a non-outbreak setting. *J Hosp Infect*  
371 2021;109:88-95.
- 372 [29] Roth JA, Hornung-Winter C, Radicke I, Hug BL, Biedert M, Abshagen C, et al. Direct Costs of a  
373 Contact Isolation Day: A Prospective Cost Analysis at a Swiss University Hospital. *Infect Control Hosp*  
374 *Epidemiol* 2018;39(1):101-3.
- 375 [30] Mehrotra P, Croft L, Day HR, Perencevich EN, Pineles L, Harris AD, et al. Effects of contact  
376 precautions on patient perception of care and satisfaction: a prospective cohort study. *Infect Control*  
377 *Hosp Epidemiol* 2013;34(10):1087-93.
- 378 [31] Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. *Jama*  
379 2003;290(14):1899-905.
- 380 [32] Lee BY, Yilmaz SL, Wong KF, Bartsch SM, Eubank S, Song Y, et al. Modeling the regional spread  
381 and control of vancomycin-resistant enterococci. *Am J Infect Control* 2013;41(8):668-73.
- 382 [33] Jurke A, Daniels-Haardt I, Silvis W, Berends MS, Glasner C, Becker K, et al. Changing  
383 epidemiology of meticillin-resistant *Staphylococcus aureus* in 42 hospitals in the Dutch-German border  
384 region, 2012 to 2016: results of the search-and-follow-policy. *Euro Surveill* 2019;24(15).
- 385 [34] Jurke A, Kock R, Becker K, Thole S, Hendrix R, Rossen J, et al. Reduction of the nosocomial  
386 meticillin-resistant *Staphylococcus aureus* incidence density by a region-wide search and follow-strategy  
387 in forty German hospitals of the EUREGIO, 2009 to 2011. *Euro Surveill* 2013;18(36):pii=20579.
- 388 [35] Bartsch SM, Wong KF, Mueller LE, Gussin GM, McKinnell JA, Tjoa T, et al. Modeling Interventions  
389 to Reduce the Spread of Multidrug-Resistant Organisms Between Health Care Facilities in a Region.  
390 *JAMA Netw Open* 2021;4(8):e2119212.

- 391 [36] Lee BY, Bartsch SM, Wong KF, McKinnell JA, Slayton RB, Miller LG, et al. The Potential Trajectory  
392 of Carbapenem-Resistant Enterobacteriaceae, an Emerging Threat to Health-Care Facilities, and the  
393 Impact of the Centers for Disease Control and Prevention Toolkit. *Am J Epidemiol* 2016;183(5):471-9.
- 394 [37] Lee BY, Bartsch SM, Wong KF, Yilmaz SL, Avery TR, Singh A, et al. Simulation shows hospitals that  
395 cooperate on infection control obtain better results than hospitals acting alone. *Health Aff (Millwood)*  
396 2012;31(10):2295-303.
- 397 [38] Maechler F, Schwab F, Hansen S, Fankhauser C, Harbarth S, Huttner BD, et al. Contact isolation  
398 versus standard precautions to decrease acquisition of extended-spectrum  $\beta$ -lactamase-producing  
399 Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. *Lancet Infect Dis*  
400 2020;20(5):575-84.
- 401 [39] Kluytmans-van den Bergh MFQ, Bruijning-Verhagen PCJ, Vandenbroucke-Grauls C, de Brauwier E,  
402 Buiting AGM, Diederens BM, et al. Contact precautions in single-bed or multiple-bed rooms for patients  
403 with extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae in Dutch hospitals: a cluster-  
404 randomised, crossover, non-inferiority study. *Lancet Infect Dis* 2019;19(10):1069-79.
- 405

406 **Table I** Transmission-based precautions during inpatient care and day admissions (n=11 hospitals).

<b>Transmission-based precautions</b>	<b>CPE</b>	<b>CPPA</b>	<b>ESBL-E</b>
<b><u>Isolation precautions during inpatient care</u></b>			
Yes	11 (100)	11 (100)	10 (90.9)
No	0 (0.0)	0 (0.0)	1 (9.1)
<b>Type of isolation</b>			
Strict isolation	1 (9.1)	1 (9.1)	0 (0.0)
Contact-plus isolation	2 (18.2)	2 (18.2)	0 (0.0)
Contact isolation	8 (72.7)	8 (72.7)	10 (90.9)
No isolation	0 (0.0)	0 (0.0)	1 (9.1)
<b><u>IPC measures during inpatient care</u></b>			
<b>Type of room<sup>1,2</sup></b>			
Isolation room with anteroom and private bathroom	2 (18.2)	2 (18.2)	0 (0.0)
Single-patient room with private bathroom	10 (90.9)	10 (90.9)	8 (72.7)
Single-patient room with shared bathroom	1 (9.1)	1 (9.1)	1 (9.1)
Multiple-occupancy room with dedicated bathroom	1 (9.1)	1 (9.1)	3 (27.3)
Multiple-occupancy room with shared bathroom	0 (0.0)	0 (0.0)	3 (27.3)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
<b>HCWs PPE: entering the patient room without patient contact<sup>3</sup></b>			
No PPE	5 (45.5)	5 (45.5)	8 (72.7)
Non-sterile gloves	1 (9.1)	1 (9.1)	1 (9.1)
Disposable gown and non-sterile gloves	4 (36.4)	4 (36.4)	1 (9.1)
Surgical mask type IIR, disposable gown, non-sterile gloves, and hair cap	1 (9.1)	1 (9.1)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
<b>HCWs PPE: entering the patient room with patient contact<sup>3</sup></b>			
Gown and gloves	10 (90.9)	10 (90.9)	10 (90.9)
IIR surgical mask, gown, gloves, and hair cap	1 (9.1)	1 (9.1)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
<b>Room door allowed to be open</b>			



Yes	6 (54.5)	7 (63.6)	9 (81.8)
No	5 (45.5)	4 (36.4)	1 (9.1)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
<b>Physiotherapy is allowed in public gym</b>			
Yes	5 (45.5)	5 (45.5)	7 (63.6)
No	4 (36.4)	4 (36.4)	1 (9.1)
Not applicable	2 (18.2)	2 (18.2)	3 (27.3)
<b>Physiotherapy in corridors and stairwells is allowed</b>			
Yes	8 (72.7)	8 (72.7)	10 (90.9)
No	3 (27.3)	3 (27.3)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
Physiotherapist with PPE	6 (75.0)	6 (75.0)	6 (60.0)
Patient with PPE	1 (12.5)	1 (12.5)	1 (10.0)
No PPE for physiotherapist or patient	1 (12.5)	1 (12.5)	2 (20.0) <sup>4</sup>
<b>Mandatory to report physiotherapy to infection prevention team</b>			
Yes	5 (55.6)	5 (55.6)	5 (45.5)
No	4 (36.4)	4 (36.4)	5 (45.5)
Not applicable	2 (18.2)	2 (18.2)	1 (9.1)
<b><u>Isolation precautions during day admissions</u></b>			
Yes	11 (100)	11 (100)	9 (81.8)
Only for a specific patient group	0 (0.0)	0 (0.0)	1 (9.1)
No	0 (0.0)	0 (0.0)	1 (9.1)
<b>Type of isolation</b>			
Strict isolation	1 (9.1)	1 (9.1)	0 (0.0)
Contact-plus isolation	2 (18.2)	2 (18.2)	1 (9.1)
Contact isolation	8 (72.7)	8 (72.7)	9 (81.8)
No isolation	0 (0.0)	0 (0.0)	1 (9.1)
<b><u>IPC measures during day admissions</u></b>			
<b>Type of room<sup>5</sup></b>			
Single-patient room	9 (81.8)	9 (81.8)	5 (45.5)
Multiple-occupancy room	1 (9.1)	1 (9.1)	4 (36.4)

Not applicable	1 (9.1)	1 (9.1)	2 (18.2)
<b>HCW PPE in treatment room<sup>3</sup></b>			
No PPE	0 (0.0)	0 (0.0)	0 (0.0)
Non-sterile gloves	0 (0.0)	0 (0.0)	0 (0.0)
Disposable gown and non-sterile gloves	10 (90.9)	10 (90.9)	10 (90.9)
Surgical mask type IIR, disposable gown, non-sterile gloves, and hair cap	1 (9.1)	1 (9.1)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
<b>Allowed to be accompanied by a visitor</b>			
Yes	11 (100)	11 (100)	10 (90.9)
No	0 (0.0)	0 (0.0)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
<b>Visitor also placed in isolation</b>			
Yes	6 (54.5)	6 (54.5)	4 (36.4)
No	5 (45.5)	5 (45.5)	6 (54.5)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)

407 Data are N (%). CPPA carbapenemase-producing *Pseudomonas aeruginosa*, CPE carbapenemase-  
 408 producing Enterobacterales, ESBL-E extended-spectrum  $\beta$ -lactamase-producing Enterobacterales, HCW  
 409 healthcare worker, IPC infection prevention and control, PPE personal protective equipment.

410 <sup>1</sup> Multiple answers per hospital possible.


411 <sup>2</sup> An isolation room is defined as a single-occupancy room with anteroom and pressure difference. A  
 412 multiple-occupancy patient room is considered to be a room in which other bed(s) may be occupied  
 413 both by carriers of the same or different resistant bacteria, and non-carriers.

414 <sup>3</sup> A disposable gown was defined as a long-sleeved gown in 10 out of 11 hospitals. Hospital 9 used a  
 415 long-sleeved gown when caring for patients in strict isolation, which this hospital applied to patients  
 416 with CPE or CPPA, and an apron when caring for patients in contact isolation, which this hospital applied  
 417 to patients with ESBL-E.

418 <sup>4</sup> One answer is missing.

419 <sup>5</sup> Procedures taking place in the day admissions centre are e.g., minor surgical procedures,  
 420 haemodialysis, hemapheresis, etc. The answer is not applicable when a patient directly goes home after  
 421 the procedure has been performed in an operating room.

422 **Figure 1** Contact precautions during outpatient care (n=11 hospitals).



423

424 Data are N (%). CPE carbapenemase-producing Enterobacterales, CPPA carbapenemase-producing *Pseudomonas aeruginosa*, ESBL-E extended-  
 425 spectrum  $\beta$ -lactamase-producing Enterobacterales, HCW healthcare workers, IPC infection prevention and control, N/A not applicable, PPE  
 426 personal protective equipment.

427 \*For policy 1, one hospital also includes patients with skin conditions and open wounds in category 1 'Outpatients, invasive procedure'.

428 **Table II** Follow-up and conditions for cessation of isolation measures for patients with CPE and CPPA (n=11 hospitals).

	Hospital 1	Hospital 4	Hospital 5	Hospital 10	Hospital 2	Hospital 3	Hospital 6	Hospital 11	Hospital 7	Hospital 8	Hospital 9
Contraindications for initiation of active follow-up or culturing	Yes, antibiotic use and hospital admission	Yes, antibiotic use	None	Yes, antibiotic use	Yes, antibiotic use and hospital admission	Yes, antibiotic use; hospital admission only for CPPA	Yes, antibiotic use	Yes, antibiotic use, drains, and wounds	N/A	N/A	N/A
Active, passive or no follow-up	Active	Active	Active	Active	Passive	Passive	Passive	Passive	No follow-up	No follow-up	No follow-up
Method of approaching patients	Self-sampling set by regular mail	Letter, followed by self-sampling set by regular mail	Self-sampling set by regular mail	Self-sampling set by regular mail	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Number of follow-up swabs	6 sets of 2 swabs	5 sets of 1 swab	1 set of 2 swabs	5 sets of 1 swab	2 sets of 3 swabs	2 sets of 1 swab	2 sets of 1 swab	2 sets of 1 swab	N/A	N/A	N/A

Body sites sampled	Throat, rectum, wounds (if present), urine and sputum for CPE (if applicable)	Rectum, urine only in case of UTI or catheter	Throat and rectum	Rectum (or faeces)	Throat, nose, rectum, wounds (if present), urine (if catheter), sputum (if productive cough, intubation or tracheostomy)	Rectum	Rectum	Rectum; wounds (if present) for CPE	N/A	N/A	N/A
Start active follow-up or culturing	Two months after first positive culture and without contra-indications	Two months after the last positive culture	At least one year after the last positive culture	Two months after the last positive culture	48 hours after stopping antibiotics	Two months after the last positive culture	At least 48 hours after stopping antibiotics	At least one year after the last positive culture	N/A	N/A	N/A

Intervals	Every two months	Every two months	N/A	Every two months	At least 24 hours	Two days	24 hours	At least 24 hours	N/A	N/A	N/A
Unflagging patient's EHR	After 6 negative culture sets	After 5 negative culture sets within 1 year	After 1 year with 1 negative culture set	After 5 negative cultures	After 2 negative culture sets <sup>1</sup>	After 2 negative cultures	Never <sup>2</sup>	After 2 negative culture sets	Never	Never	Never

429 CPPA carbapenemase-producing *Pseudomonas aeruginosa*, CPE carbapenemase-producing Enterobacterales, N/A not applicable, UTI urinary  
430 tract infection.

431 Blue columns indicate passive follow-up of carriers. Number and frequency of cultures described in the blue columns represents the cultures  
432 needed for safe cessation of isolation measures during hospitalization.

433 <sup>1</sup> Electronic label is changed to 'Multidrug-resistant microorganism in the past', which means that patients are screened during each subsequent  
434 hospitalization.

435 <sup>2</sup> Electronic label remains at all times, however, isolation measures are scaled down in case screening cultures are negative after one year.  
436 Patients are screened during each subsequent hospitalization.

437 **Table III** Follow-up and conditions for cessation of isolation measures for patients with ESBL-E (n=11 hospitals).

	Hospital 1	Hospital 5	Hospital 3	Hospital 6	Hospital 11	Hospital 8	Hospital 9	Hospital 4	Hospital 10	Hospital 7	Hospital 2
Contraindications for initiation of active follow-up or culturing	Yes, antibiotic use and hospital admission	None	Yes, antibiotic use	Yes, antibiotic use	Yes, antibiotic use, drains, and wounds	Yes, antibiotic use	Yes, antibiotic use, hospital admission <sup>1</sup> , catheter, drains, wounds	Yes, antibiotic use	N/A	N/A	N/A
Active, passive or no follow-up	Active	Active	Passive	Passive	Passive	Passive	Passive	Passive	No follow-up	No follow-up	N/A
Method of approaching patients	Self-sampling set by regular mail	Self-sampling set by regular mail	N/A	N/A	N/A	On admission	On admission	On admission	N/A	N/A	N/A
Number of follow-up swabs	2 sets of 2 swabs	1 set of 2 swabs	2 sets of 1 swab	2 sets of 1 swab	2 sets of 1 swab	1 set of 1 swab	1 set of 1 swab	1 set of 1 swab	N/A	N/A	N/A

Body sites sampled	Throat, rectum, wounds (if present), urine (if applicable)	Throat and rectum	Rectum	Rectum	Rectum; wounds (if present)	Rectum; wounds (if present); urine (if catheter); sputum (if productive cough)	Rectum (throat in neonates); wounds (if present); urine (if catheter); sputum (if productive cough or intubation).	Rectum; urine (if applicable)	N/A	N/A	N/A
Start active follow-up or culturing	Two months after first positive culture and without contra-indications	At least one year after the last positive culture	Two months after first positive culture	At least 48 hours after stopping antibiotics	At least one year after the last positive culture	One year after first positive culture	At least one year after first positive culture	N/A	N/A	N/A	N/A
Intervals	Three days between	N/A	Two days between	24 hours	At least 24 hours	N/A	N/A	N/A	N/A	N/A	N/A



	culture sets		culture sets								
Unflagging patient's EHR	After 2 negative culture sets	After 1 year with 1 negative culture set	After 2 negative culture sets	Never <sup>2</sup>	After 2 negative culture sets	After 1 year with 1 negative culture set	After at least one year with 1 negative culture set	After 1 year	After 1 year	After 1 year	After 1 year

438 *ESBL-E* extended-spectrum  $\beta$ -lactamase-producing Enterobacterales, *N/A* not applicable.

439 Blue columns indicate passive follow-up of carriers. Number and frequency of cultures described in the blue columns represents the cultures  
 440 needed for safe cessation of isolation measures during hospitalization.

441 <sup>1</sup> Only during the initial clinical admission (i.e., when *ESBL-E* is first detected in a patient), hospital admission is considered a contraindication for  
 442 culturing in order to declare the patient *ESBL-E* negative.

443 <sup>2</sup> Electronic label remains at all times, however, isolation measures are scaled down in case screening cultures are negative after one year.  
 444 Patients are screened during each subsequent hospitalization.

445 **Supplementary material**

446 Supplementary Table A1: Characteristics of the eleven hospitals from the Southwest region of the  
447 Netherlands.

448 Supplementary Table A2: IPC measures recommended by the Dutch, ESCMID and ECDC guidelines.

449 Supplementary Table A3: IPC measures for visitors of inpatients (n=11 hospitals).

450 Supplementary Table A4: Cleaning and disinfection after discharge of the patient (n=11 hospitals).